Top Trends In Erectile Dysfunction Drugs Market 2020 – 2023 By Growth Factors And Industry Players Overview

Erectile Dysfunction Drugs Market Scenario

Global erectile dysfunction drugs market size is expected to register a CAGR of 3.5% during the forecast period of 2019 to 2025 with a market value of USD 2930 million in 2025.

Erectile dysfunction (ED) is defined as persistent difficulty achieving and maintaining an erection sufficient to have sex.

The global erectile dysfunction drugs market is driven by factors such as increasing number of men suffering from this disorder, rising geriatric population and patent expiry of number of blockbuster drugs.

Additionally, increasing manufactures of generic drugs coupled with rising adoption of a sedentary lifestyle along with the associated stress is anticipated to fuel the market growth.

For instance, according to The Massachusetts Male Aging Study (MMAS), worldwide incidence of erectile dysfunction will increase from 152 million men in 1995 to 322 million men by the year 2025.

Browse Sample of the Report @

On the other hand, poor patient adherence to erectile dysfunction drugs is projected to hamper the growth of the market during the assessment period.

Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.

For instance, in December 2017, Teva Pharmaceutical Industries Ltd. announces exclusive launch of a generic version viagra tablets in the US.

Erectile Dysfunction Drugs Market Segmentation

The global erectile dysfunction drugs market has been segmented based on and region.

The market, based on drug, has been bifurcated into viagra (sildenafil citrate), cialis (tadalafil), staxyn/levitra (vardenafil), stendra/spedra (avanafil), zydena (udenafil), vitaros (alprostadil cream), and others. The market, on the basis of end user, has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Based on drug, viagra segment is expected to hold a major share in the market as it is the first Food and Drug Administration (FDA) approved oral treatment for erectile dysfunction. In 1998, Pfizer introduced viagra which is dominating the erectile dysfunction market. Cialis segment is expected to be the fastest growing segment as cialis provides an erection over a longer period than viagra, cialis lasts up to 18 hours, while viagra only lasts for about 4 to 6 hours.

On the basis of end user retail pharmacy segment is expected to be the largest segment as it is available easily in the retail stores. The hospital pharmacy segment is expected to be the fastest growing segment as increasing pool of patient due to increasing awareness and patient education.

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The erectile dysfunction drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European erectile dysfunction drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The erectile dysfunction drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The erectile dysfunction drugs market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

The key players in the global erectile dysfunction drugs market are Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.

Browse More Details of the Report @